AI

Vaccine
#AI #Antibody drug conjugate (ADC) #Biopharma #Drug discovery #Vaccines

DDW Fall issue out now

The DDW Fall issue is out now and examines why there is a need for a universal pneumococcal vaccine, why China might be the next global biopharma powerhouse and looks at developments in microbiome research and the therapeutic sectors it is driving. It also features an exclusive guide exploring… Read More

#News

#AI #Drug development #Life sciences

State-of-the-art life sciences hub opened in London

Victoria House has been officially opened in London’s Bloomsbury Square as the capital’s state-of-the-art life sciences hub. The building was opened on Tuesday at a launch event which brought together leaders from science, academia, venture capital and the UK parliament. It is hoped Victoria House can help the UK achieve… Read More

#News

Robot holds up a pill
#AI #AI / data analytics / healthtech / informatics #Drug discovery #Generative AI

From knowledge to creation: keeping up with AI 

Generative AI is now rapidly disrupting entire industries and new technology breakthroughs are emerging at pace. As new iterations push the boundaries of deep research and insight generation, the implications for life sciences are both profound and uncertain. Reflecting on the rapid progression of GenAI, and its potential to propel… Read More

#Exclusive Content

Molecules
#AI #AI / data analytics / healthtech / informatics #Compounds #Drug discovery #Library screening

The evolution of chemical collections and drug-like diversity 

Andrea Altieri, Chief Scientific Officer, and Diana Zelencova-Gopejenko, Chief Executive Officer, Molport, explore how curated compound libraries—and the platforms that support them—are transforming the landscape of modern screening campaigns in drug discovery.  The development of screening libraries has closely followed advances in medicinal chemistry, computational methods, and molecular biology. In… Read More

#Exclusive Content

#AI #Dermatology #Drug discovery

Almirall and Absci extend partnership tackling dermatological conditions  

Biopharmaceutical companies Almirall and Absci have announced an expansion of their ongoing partnership targeting dermatological indications.   The expansion of the collaboration follows the successful delivery of AI-designed, functional antibody leads against a difficult-to-drug target—the first target addressed within the initial collaboration between Almirall and Absci.  … Read More

#News

Trophy
#AI #Cancer research #Drug discovery #Nebius #Protein targets #Transcriptomics

Nebius accelerates next generation of AI discovery innovation

DDW’s Megan Thomas attended Nebius’ inaugural AI Discovery Awards in Amsterdam, where top prizes of $100,000 in GPU credits were awarded to four companies pioneering AI breakthroughs in cancer prediction, protein targeting, transcriptomic mapping, and precision diagnostics. The winners were selected from 257 global applications by a panel of 19… Read More

#News

#AI #Career #Clinical trials #Drug discovery #Infectious diseases #Meet the Researcher #Oncology #Poolbeg Pharma

Meet the researcher: Liam Tremble

DDW’s Megan Thomas looks at a day in the life of Liam Tremble, Principal Scientist at Poolbeg Pharma. 1. Where do you work, and can you tell us what you’re working on at the moment?   I work at Poolbeg Pharma, where we are developing novel treatments for diseases with unmet… Read More

#Exclusive Content #Opinion

Robot holds up a pill
#AI #BioXcel Therapeutics #Drug discovery #Drug repurposing

New podcast: Are we close to an AI drug revolution?

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr Friso Postma,… Read More

#News

#AI #Drug repurposing #Large language model (LLM)

What AI offers drug repurposing  

DDW Editor Reece Armstrong speaks to Jouhyun Jeon, Principal Investigator at Klick Applied Sciences, about the company’s artificial intelligence algorithm, LOVENet, and how it offers a fresh perspective for repurposed drugs.   RA: First off, could you tell me about the LOVENet algorithm?  JJ: LOVENet (a Large Optimized Vector Embeddings Network)… Read More

#Exclusive Content

#AI #Biomarkers #Clinical trials #Collaboration #Digital biomarkers #Nucleai #Precision medicine #Proscia

Proscia teams up with Nucleai to improve access to AI biomarkers

Software company Proscia has partnered with spatial AI biomarker company Nucleai in a collaboration aimed at improving precision medicine biomarkers for clinical trials.   The companies are integrating Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and will make them available as part of Proscia’s precision medicine AI portfolio.    The… Read More

#Business & Investment #News

Human heart
#AI #AstraZeneca #BenevolentAI #Collaboration #Drug discovery #Heart failure #Target identification

AI collaboration shows success for novel heart failure target  

AstraZeneca has added a novel target for heart failure to its discovery portfolio through its collaboration with BenevolentAI.  This novel target for heart failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca. This is the first target to be selected from the extended… Read More

#News

#AI #Cancer research #Collaboration #Drug development #Lantern Pharma #Metabolic inhibitor #Oregon Therapeutics #Protein disulfide isomerase (PDI)

AI collaboration to optimise development of cancer inhibitor drug 

Lantern Pharma has entered a strategic AI-driven collaboration with French biotechnology company Oregon Therapeutics to optimise the development of its first-in-class protein disulfide isomerase (PDI)1 inhibitor drug candidate XCE853 in novel and targeted cancer indications.   Lantern will be leveraging its RADR AI platform to uncover biomarkers and efficacy-associated signatures of XCE853 across solid… Read More

#Business & Investment #Cancer Research #News

Paris
#AI #Antibody drug conjugate (ADC) #DNA #ESMO #ESMO Targeted Anticancer Therapies Congress 2024 #RNA #Storm Therapeutics

Conversations from ESMO Targeted Anticancer Therapies Congress 2024 

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. Rausch gave an update on the latest developments from… Read More

#Exclusive Content

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #Gene expression #Gene mutation #Interview #mRNA #Next generation sequencing #Oncology #PharmEnable #RNA sequencing #Single-cell RNA sequencing #Vaccines

Podcast: What trends will speed up the journey from clinic to bedside?

This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable, Is single-cell… Read More

#News

Respiratory system
#AI #Anima Biotech #Idiopathic pulmonary fibrosis #Lung disease #mRNA #Preclinical investigations

AI mRNA candidate shows early promise in lung fibrosis

A therapeutic candidate which operates through a novel mRNA biology mechanism of action could open new avenues for treating idiopathic pulmonary fibrosis (IPF) patients. Anima Biotech has identified a preclinical candidate, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts. By inhibiting myofibroblasts’… Read More

#News

Pancreatic cancer
#AI #ASCO #Cancer research #Clinical trials #FDA #Neurology #Oncology #Orphan drugs #Pancreatic cancer #Rare disease

Phase IIa results for combination pancreatic cancer therapy  

BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, has announced new data from a Phase IIa clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held 18-20 January 2024, in San Francisco. Read More

#Cancer Research #News